Best of cancer media

Curated. One-line gists, outbound links, topic tags. Updated as new must-reads appear.

Tweets / threads

@NEJM — DeLLphi-305 published SCLC — Tarlatamab–durvalumab maintenance in extensive-stage SCLC; original article posted at ESMO 2026.
@NEJM — Krascendo 1 result lung · KRAS G12C — Divarasib vs sotorasib/adagrasib in pretreated KRAS G12C NSCLC; PFS 9.8 months headline.
@DrChoueiri — Krascendo 1 live lung · KRAS G12C — Trialist’s take from the room: PFS 9.8 vs 5.7 mo, HR 0.58.
@DrChoueiri — SAFFRON lung · EGFR/MET — Osimertinib + savolitinib vs platinum/pemetrexed after osimertinib in EGFRm/MET+ disease.
@myESMO — HARMONi-GI1 biliary — Ivonescimab (PD-1/VEGF bispecific) + chemo improved OS in biliary tract cancer.
@myESMO — claudin 18.2 ADCs gastric · ADC — Phase III Presidential Symposium data for two claudin 18.2 ADCs.
@myESMO — cancer vaccines explained melanoma · vaccine — Sapna Patel on what INTerpath-001 means for patients.
@OncoAlert — DASL-HiCaP video prostate — Portuguese-language video take on DASL-HiCaP in localized prostate cancer.

ATOMIC: adjuvant IO in dMMR colon cancer colon · MSI — Thread on adding atezolizumab to adjuvant FOLFOX in stage III dMMR colon cancer.
HER2CLIMB-05: maintenance intensifies breast · HER2 — Tucatinib added to HER2 maintenance after first-line induction — what it means for practice.
PSMAddition: radioligands move earlier prostate — Lu-PSMA-617 brought into hormone-sensitive metastatic prostate cancer.
FDA oncology approvals, October 2026 regulatory — One-thread roundup of the month’s FDA oncology approvals.

@NEJM — clinical trial prediction markets trials · ethics — NEJM Perspective: do betting markets on trial outcomes inform or distort? Who pays the cost?
@DrChoueiri — CARE1 PD-L1 testing kidney · biomarker — 90% local vs central PD-L1 concordance in mRCC — groundwork for biomarker-guided debate.
@DrChoueiri — LITESPARK-011 QoL kidney · QoL — Baseline QoL tracked with PFS/OS (exploratory) — prognostic or confounding?

NCI Cancer Currents blog general — NCI’s plain-language research news; reliable first read on new trials.
Cancer Research UK — how cancer starts patient explainer — Clear explainer of genes, cells and how cancer develops.
Cancer Research UK — immunotherapy immunotherapy — Patient-friendly guide to types and side effects of immunotherapy.
Cancer Research UK — causes of cancer prevention — Evidence-graded guide to real vs myth risk factors.
The Cancer Letter policy — Investigative oncology journalism — FDA, NCI, drug pricing.

KEYNOTE-024 — NEJM 2016 lung — Pembrolizumab beat chemotherapy first-line in PD-L1 ≥50% NSCLC; launched IO monotherapy era.
Le et al. — PD-1 blockade in MMR-deficient tumors, NEJM 2015 MSI · pan-tumour — Mismatch-repair deficiency predicted response to PD-1 blockade across tumour types.
PACIFIC — NEJM 2017 lung · stage III — Durvalumab consolidation after chemoradiation in unresectable stage III NSCLC.
DESTINY-Breast04 — NEJM 2022 breast · HER2-low — T-DXd in HER2-low disease created a new treatable category.
Cercek et al. — dostarlimab in dMMR rectal cancer, NEJM 2022 rectal · MSI — PD-1 blockade alone in locally advanced dMMR rectal cancer; organ-sparing possibility.
CheckMate 227 — NEJM 2019 lung — Nivolumab + ipilimumab chemo-free option in advanced NSCLC.
KRYSTAL-1 CRC — NEJM 2023 colorectal · KRAS G12C — Adagrasib ± cetuximab in KRAS G12C colorectal cancer; EGFR co-blockade matters.

VJOncology (YouTube) conference interviews — Short expert interviews from ASCO, ESMO, ASH and others.
ASCO on YouTube ASCO — Official ASCO talks, plenary discussions and expert interviews.
ecancer video global oncology — Open-access interviews with investigators, strong LMIC coverage.
ESMO Daily Reporter ESMO — Congress news with expert commentary on each key trial.

Mumbai breast screening trial — BMJ 2021 breast · screening — 20-year results of clinical breast exam screening in Mumbai; central to the India screening debate.
Lancet Oncology 2014 — cancer control in China, India, Russia India · policy — Commission-style analysis of access, cost and workforce gaps — still debated.
PACIFIC vs CheckMate 227: chemo-free IO in lung? lung · debate — When is dual IO enough? Read alongside KEYNOTE-024 for the PD-L1 debate.

For Indian context see ICMR and the National Cancer Grid — resource-stratified guidelines matter when drug access varies.